LogicBio announces pricing of public offering (1138369)

 
 Arix Bioscience PLC (ARIX) 
LogicBio announces pricing of public offering 
 
01-Oct-2020 / 14:40 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
 
                            Arix Bioscience plc 
 
               LogicBio announces pricing of public offering 
 
  LONDON, 01 October 2020: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global 
   venture capital company focused on investing in and building breakthrough 
          biotech companies, today notes that its portfolio company LogicBio 
Therapeutics, Inc. (NASDAQ: LOGC) ("LogicBio"), has announced the pricing of 
its underwritten public offering in the United States of 7,000,000 shares of 
common stock, at a public offering price of $6.00 per share, for total gross 
      proceeds of approximately $42.0 million, before deducting underwriting 
     discounts and commissions and offering expenses payable by LogicBio. In 
 addition, LogicBio has granted the underwriters a 30-day option to purchase 
up to an additional 1,050,000 shares of common stock, at the public offering 
 price less underwriting discounts and commissions. The offering is expected 
to close on 5 October 2020, subject to the satisfaction of customary closing 
                                                                 conditions. 
 
  Arix has agreed to invest $3.0 million in the offering and retains a stake 
                                                        of 9.4% in LogicBio. 
 
    The shares of common stock described above are being offered by LogicBio 
 pursuant to an effective shelf registration statement on Form S-3 (File No. 
        333-234735), which was declared effective by the U.S. Securities and 
   Exchange Commission ("SEC") on 25 November 2019. A preliminary prospectus 
   supplement related to the offering was filed with the SEC on 30 September 
 2020. The final prospectus supplement related to the offering will be filed 
 with the SEC. When available, you may obtain copies of the final prospectus 
  supplement and the accompanying prospectus from: Jefferies LLC, Attention: 
   Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, NY 
                        10022, by telephone: [phone], or by email: 
  [e-mail], Barclays Capital Inc., c/o Broadridge 
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 
  [phone], or email: [e-mail], or William 
        Blair & Company, L.L.C., Attention: Prospectus Department, 150 North 
                          Riverside Plaza, Chicago, IL 60606, or by email at 
  [e-mail] or by telephone at [phone]. Electronic 
   copies of the final prospectus supplement and the accompanying prospectus 
will also be available on the website of the SEC at www.sec.gov [1]. For the 
  avoidance of doubt, such prospectus will not constitute a "prospectus" for 
     the purposes of Directive 2003/71/EC (and amendments thereto, including 
  Directive 2010/73/EU, to the extent implemented in each relevant EU member 
 state) and will not have been reviewed by any competent authority in any EU 
                                                               member state. 
 
This press release does not constitute an offer to sell or a solicitation of 
 an offer to buy the securities in the offering, nor shall there be any sale 
  of these securities in any jurisdiction in which an offer, solicitation or 
     sale would be unlawful prior to registration or qualification under the 
                                       securities laws of such jurisdiction. 
 
                                   [ENDS] 
 
                                                                   Enquiries 
 
                               For more information on Arix, please contact: 
 
                                                         Arix Bioscience plc 
 
                                 Charlotte Parry, Head of Investor Relations 
 
                                                         [phone] 
 
                                                [e-mail] 
 
                                            Optimum Strategic Communications 
 
                                                  Mary Clark, Supriya Mathur 
 
                                                     T: [phone] 
 
                                               [e-mail] 
 
                                                   About Arix Bioscience plc 
 
Arix Bioscience plc is a global venture capital company focused on investing 
 in and building breakthrough biotech companies around cutting edge advances 
 in life sciences. We collaborate with exceptional entrepreneurs and provide 
   the capital, expertise and global networks to help accelerate their ideas 
into important new treatments for patients. As a listed company, we are able 
   to bring this exciting growth phase of our industry to a broader range of 
                                                                  investors. 
 
               For more information please visit: www.arixbioscience.com [2] 
 
ISIN:          GB00BD045071 
Category Code: MSCM 
TIDM:          ARIX 
LEI Code:      213800OVT3AHQCXNIX43 
Sequence No.:  85286 
EQS News ID:   1138369 
 
End of Announcement EQS News Service 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=9adf90716a79391bb60d3fe285736534&application_id=1138369&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=889c637ce21c3a47a35c39202ebd9825&application_id=1138369&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

October 01, 2020 09:40 ET (13:40 GMT)